Moxifloxacin is a Medicine belongs to FLUOROQUINOLONES group whose information about Brand can be referenced from   Book : Martindale    Page : 326   Edition : 38,    Page :   Edition : ,

  ►   Brandname : Moxicip,Moxif,Avelox,Avelox,Vigamox,Moxiflox

  ►  Strength : Tablet with 400  mg, Injection with 400  mg,

Reference of this Medicine for its Strength can be taken from   Book : Basic & Clinical pharmacology    Page : 838   Edition : 12,
A Route of administration in pharmacology and toxicology is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration.

  ►  Route of administration : Topical, IV, Oral,
Reference :-   Book : Martindale    Page : 326   Edition : 38,

Dosing of Medicine differ in Adult & Pediatrics ↓


Adult Dose

S.No Ailment   Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency   Additional Info
1 Acute bacterial sinusitis Oral 400 mg Tablet o.d.
2 Susceptible infections Oral 400 mg Tablet Respiratory, skin and skin structure, and intra-abdominal infections.
3 Bacterial conjunctivitis Topical 0.5 % Eye Drop

Ref :-  Book : Martindale    Page : 326   Edition : 38,




Pediatric Dose

S.No Ailment   Age Min   Age Max   Weight ( Kg ) Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency  Additional Info  

Ref :- Book :
Precaution :- If a Patient is using 'Moxifloxacin' drug in  Generalized, Tonic-Clonic Seizures  disease, then Please Not to be given .

►  Side Effect : nausea, vomiting, diarrhea, abdominal pain, dyspepsia, headache, Dizziness, Confusion, insomnia, Restlessness, tremor, drowsiness, nightmares, sensory disturbances, hallucinations, psychotic reactions, Depression, convulsion, intracranial hypertension, paraesthesia, peripheral neuropathy, rash, pruritus, photosensitivity, anaphylaxis, arthralgia, myalgia, tendon rupture, Crystalluria, transient increases in serum creatinine or blood urea nitrogen, Elevated liver enzyme values, jaundice, hepatitis, eosinophilia, leucopenia, thrombocytopenia, tachycardia, hypotension, oedema, syncope, hot flushes, sweating, Local burning or discomfort, keratopathy, corneal staining, corneal precipitates or infiltrates, photophobia, Local discomfort, Pain, Pseudomembranous colitis, Pancreatitis, dysphagia, vasculitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, Acute renal failure, secondary to interstitial nephritis, pancytopenia, haemolytic anaemia, agranulocytosis, torsade de pointes,
Ref :-   Book : Martindale    Page : 262   Edition : 38,

►  Drug Interaction : Drug interaction of Moxifloxacin is with NA

  ►    Mechanism of Drug Drug Interaction :  Fluoroquinolones, are known to inhibit the cytochrome P450 isoenzyme CYP1A2 and may increase plasma concentrations of drugs, such as tizanidine, that are metabolised by this isoenzyme. Use of ciprofloxacin with tizanidine is contra-indicated. Ciprofloxacin is reported to enhance the effect of oral anticoagulants such as warfarin and the oral antidiabetic glibenclamide. Renal tubular secretion of methotrexate may be inhibited by ciprofloxacin, potentially increasing its toxicity. Cations such as aluminium, calcium, magnesium, or iron reduce the absorption of oral ciprofloxacin or related drugs when given together. Changes in the pharmacokinetics of fluoroquinolones have been reported when given with histamine H2 antagonists, transient increases in serum creatinine have occurred when ciprofloxacin is given with ciclosporin. Altered serum concentrations of phenytoin have been reported in patients also receiving ciprofloxacin. Some fluoroquinolones have the potential to prolong the QT interval and should be avoided in patients also receiving class Ia antiarrhythmic drugs (such as quinidine and procainamide) or class III antiarrhythmics (such as amiodarone and sotalol). ,
Ref :-   Book : Martindale    Page : 264   Edition : 38,


►  Contraindication : Tendon pain, Epilepsy, G6PD deficiency, renal impairment, myasthenia gravis,
Ref :-   Book : Martindale    Page : 326   Edition : 38,
  ►  Mechanism of Action :   Inhibit bacterial type II topoisomerases. At therapeutic concentrations, quinolones have a bacterial effect by causing dissociation of the topoisomerase from cleaved DNA, leading to double-stranded DNA. ,
Ref :-   Book : Martindale    Page : 596   Edition : 37,

Pathway of Dietry Product


​   ► Act.Comp / Nutrient / Food / Herb as follows :- Eyebright with Another pathway,

  ►  Pathway with its reference as follows :-
  • anti-infective --- ( PDR for Herbal medicines. (2000) (4th ed.). U.S. )

  •   ►  URL -- http://www.travolekar.ru/arch/Pdr_for_Herbal_Medicines.pdf,


    Dietry Substance Interactions


    ​   ► This Medicine interact with :- VITAMIN K with Increase in Nutrient Level, CALCIUM with Decrease in Nutrient Level, MAGNESIUM with Decrease in Nutrient Level, MAGNESIUM with Decrease in Nutrient Level,

      ►  Reference :-
  • Gaby, A. (2006). A–Z Guide to Drug-Herb-Vitamin Interactions. 2nd ed. New York: Three Rivers Press
  • Gaby, A. (2006). A–Z Guide to Drug-Herb-Vitamin Interactions. 2nd ed. New York: Three Rivers Press
  • Gaby, A. (2006). A–Z Guide to Drug-Herb-Vitamin Interactions. 2nd ed. New York: Three Rivers Press
  • Gaby, A. (2006). A–Z Guide to Drug-Herb-Vitamin Interactions. 2nd ed. New York: Three Rivers Press

  •   ►  URL -- http://www.otto-wipfel.co.uk/otto/supplements-medication/DRUG-HERB-VITAMINS-INTERACTIONS-A-Z_Guide.pdf,


    ContraIndication Dietry Substance


    ​   ► This Medicine contraindicate with :- NA

    ►   Route of Elimination :   Fecal, Renal,
    Ref :-   Book : Martindale    Page : 326   Edition : 38,


    ►    Plasma Half-life :
      Min value :-   12 hours,    Max value :-   NA
    Ref :-   Book : Martindale    Page : 326   Edition : 38,

    ►    Peak Plasma Concentration :   Min value :-   2 hours,    Max value :-   NA
    Ref :-   Book : Basic & Clinical pharmacology    Page : 1957   Edition : 12,